Categories Earnings, Retail

What to expect when Overstock (OSTK) reports Q3 earnings?

Overstock.com Inc. (NASDAQ: OSTK) is scheduled to report third quarter 2019 earnings results on Tuesday, November 12, before the market opens. Analysts estimate the company will report a loss of $0.62 per share on revenue of $376.2 million. This compares to a loss of $1.58 per share on revenue of $440.5 million reported a year earlier.

This will be the first earnings report after Jonathan Johnson took over as CEO in September following the departure of Patrick Byrne in August. Any new plans or strategies will be worth noting.

Overstock remains confident in its retail strategy and the company anticipates achieving sustainable growth in its retail business aided by its supply chain initiatives as well as a rise in organic traffic. The company was considering the sale of its retail business but as the division gains strength, the online retailer is likely to hold on to it. It remains to be seen how the retail business performs during the upcoming holiday season.

Also read: Overstock Q2 2019 Earnings Call Transcript

The topline numbers are likely to be impacted by higher costs in the third quarter due to tariffs. The delay in the integration of a new freight carrier has led to higher freight costs as well. Last quarter, Overstock managed to reduce its marketing expenses significantly which benefited the bottom line numbers. The rise in costs could put pressure on earnings in the third quarter.

In the second quarter of 2019, Overstock missed revenue estimates but reported a narrower-than-expected loss. Revenue fell 23% to $373.7 million while net loss amounted to $0.69 per share.

Shares of Overstock have fallen 27% year-to-date and 12% over the past one month. The stock has an average 12-month price target of $44.00.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top